Area of research
Infectious Diseases · Genetics
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, Hemoglobinopathies and Related Disorders, CAR-T cell therapy research, and COVID-19 Clinical Research Studies.
Key SARS-CoV-2 testing strategies implemented in the UK: rationale and impact
The Role of Public Health Agencies in Creating Vaccine Policy.
Progress in the Development of N-of-1 Therapy.
Restoring Confidence in Public Health.
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy.
Achieving Diversity Through Decentralization.
Defining the Rates of Rare COVID-19 Vaccine-Related Adverse Events.
Biological therapies need definitive randomized controlled clinical trials.
Synergistic Strategies to Accelerate the Development of Function-Promoting Therapies: Lessons From Operation Warp Speed and Oncology Drug Development.
End of a Declared Public Health Emergency - Implications for U.S. Emergency Use Authorizations.
Intradermal Vaccination for Monkeypox - Benefits for Individual and Public Health.
Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy.
BENEFIT-RISK ASSESSMENT OF COVID-19 VACCINE, MRNA (MRNA-1273) FOR MALES AGE 18-64 YEARS
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors.
Evidence generation and reproducibility in cell and gene therapy research: A call to action
Toward a new framework for the development of individualized therapies.
Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma
Clarifying US regulations on xenotransplantation.
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
What regulators must learn from COVID-19.
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
Scientific considerations for global drug development.
Drug Regulation in the Era of Individualized Therapies.